Every 424B that Cbdmd Inc (YCBD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow YCBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YCBD filings page.
cbdMD, Inc. registers 2,000,000 shares of common stock for resale by selling shareholders, consisting of shares issuable upon conversion of Series C Convertible Preferred Stock, assuming a $1.13 conversion price. The company will receive no proceeds from these resales. The filing states 10,495,561 shares of common stock outstanding as of February 19, 2026. The Series C Preferred Stock accrues dividends at 10% per annum and is subject to a 4.99% beneficial ownership limitation and an Exchange Cap that prevents issuance above 19.99% of outstanding common stock without shareholder approval.
cbdMD, Inc. is registering 3,234,000 shares of common stock for potential resale by C/M Capital Master Fund, LP, tied to a committed equity line of up to $20,000,000. The registered shares include up to 3,154,000 purchase shares the company may sell to the investor and up to 80,000 commitment shares issued as fees.
cbdMD will not receive proceeds from the resale of these shares, but can raise cash by selling stock to the investor at a 5% discount to recent trading prices over a period of up to 36 months, subject to a 19.99% NYSE American share cap and a 4.99%–9.99% beneficial ownership limit. Management highlights recent progress reducing operating losses, new products like the Oasis beverage brand, but also discloses a going concern opinion and warns of dilution and stock-price pressure if substantial shares are issued under this financing.
cbdMD, Inc. is registering up to 1,700,000 shares of common stock for potential resale by investors who purchased its Series B Convertible Preferred Stock in a prior private placement. The company will not receive any proceeds from these resales; it already raised $1,700,000 of gross proceeds when it issued 1,700,000 Series B shares on September 29, 2025 for working capital and general corporate purposes.
Each Series B share converts at $1.00 per share, subject to anti-dilution adjustments with a $0.50 floor, and pays a 10% annual dividend in stock or cash if certain equity conditions are met. As of December 19, 2025, cbdMD had 8,959,410 common shares outstanding, which would increase to 10,659,410 if all Series B shares convert at $1.00.
The preferred stock is senior to common in a liquidation and includes a 4.99% beneficial ownership cap per holder and a 19.99% NYSE American exchange cap (1,782,518 shares) unless shareholders approve a larger issuance. Management reports fiscal 2025 progress with GAAP operating loss reduced from $3.3 million to $2.1 million, while expanding its Oasis hemp-derived beverage brand amid increasing state and federal regulatory pressures on the hemp industry.